68 related articles for article (PubMed ID: 2596062)
1. [Immunomodulating activity of natural killers in patients with breast tumors using vasopressin and interleukin 2 in vitro].
Andrianov IG; Dobkin AN; Kiselev OI; Okulov VB; Semiglazov VF
Vopr Onkol; 1989; 35(10):1186-91. PubMed ID: 2596062
[TBL] [Abstract][Full Text] [Related]
2. [Functional activity of the natural killers and macrophages in patients with breast tumors].
Andrianov IG; Voronov SM; Dobkin AN; Okulov VB; Orlov AB
Vopr Onkol; 1988; 34(12):1455-60. PubMed ID: 3265236
[TBL] [Abstract][Full Text] [Related]
3. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer.
Konjević G; Spuzić I
Neoplasma; 1993; 40(2):81-5. PubMed ID: 8350959
[TBL] [Abstract][Full Text] [Related]
4. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
5. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
6. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
7. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
Brenner BG; McCrea EL; Margolese RG
Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
[TBL] [Abstract][Full Text] [Related]
8. [The effect of autoplasma of patients with breast cancer on the functional activity of natural killer cells and adhering mononuclear cells in peripheral blood in vitro].
Andrianov IG; Katashkova TN
Eksp Onkol; 1989; 11(5):64-6. PubMed ID: 2791959
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
Silva MR; Parreira A; Ascensão JL
Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
11. [NK (natural killer) and K (killer) cell activity in breast cancer. Relation of the stage of the disease to cytotoxic activity].
Garam T; Bakács T; Tótpál K; Svastits E; Ringwald G; Petrányi G
Orv Hetil; 1983 Jan; 124(1):15-8. PubMed ID: 6828317
[No Abstract] [Full Text] [Related]
12. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A
Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
[TBL] [Abstract][Full Text] [Related]
14. [Functional interaction between the tumor necrosis factor and interleukin 2 during induction of lymphokine activated killer cytotoxic activity].
Blay JY; Bertoglio J; Gay F; Fradelizi D; Chouaib S
C R Acad Sci III; 1988; 307(2):47-51. PubMed ID: 3138005
[TBL] [Abstract][Full Text] [Related]
15. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
16. [Disorders of the immune system in benign lesions and cancer of the breast].
Derevnina NA; Polevaia EB; Veskova TK; Trubcheninova LP; Bogatyrev VN
Vopr Onkol; 1989; 35(7):810-6. PubMed ID: 2788960
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
18. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
19. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
20. Decreased response to interleukin-2 of cancer patients in terms of augmentation of natural killer cell activity.
Abe Y; Ajitsu S; Hamuro J; Ishikawa M; Sendo F
Jpn J Cancer Res; 1985 Oct; 76(10):1003-7. PubMed ID: 3935618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
